Cargando…

Molecular tuning of farnesoid X receptor partial agonism

The bile acid-sensing transcription factor farnesoid X receptor (FXR) regulates multiple metabolic processes. Modulation of FXR is desired to overcome several metabolic pathologies but pharmacological administration of full FXR agonists has been plagued by mechanism-based side effects. We have devel...

Descripción completa

Detalles Bibliográficos
Autores principales: Merk, Daniel, Sreeramulu, Sridhar, Kudlinzki, Denis, Saxena, Krishna, Linhard, Verena, Gande, Santosh L., Hiller, Fabian, Lamers, Christina, Nilsson, Ewa, Aagaard, Anna, Wissler, Lisa, Dekker, Niek, Bamberg, Krister, Schubert-Zsilavecz, Manfred, Schwalbe, Harald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6606567/
https://www.ncbi.nlm.nih.gov/pubmed/31266946
http://dx.doi.org/10.1038/s41467-019-10853-2
_version_ 1783431918593769472
author Merk, Daniel
Sreeramulu, Sridhar
Kudlinzki, Denis
Saxena, Krishna
Linhard, Verena
Gande, Santosh L.
Hiller, Fabian
Lamers, Christina
Nilsson, Ewa
Aagaard, Anna
Wissler, Lisa
Dekker, Niek
Bamberg, Krister
Schubert-Zsilavecz, Manfred
Schwalbe, Harald
author_facet Merk, Daniel
Sreeramulu, Sridhar
Kudlinzki, Denis
Saxena, Krishna
Linhard, Verena
Gande, Santosh L.
Hiller, Fabian
Lamers, Christina
Nilsson, Ewa
Aagaard, Anna
Wissler, Lisa
Dekker, Niek
Bamberg, Krister
Schubert-Zsilavecz, Manfred
Schwalbe, Harald
author_sort Merk, Daniel
collection PubMed
description The bile acid-sensing transcription factor farnesoid X receptor (FXR) regulates multiple metabolic processes. Modulation of FXR is desired to overcome several metabolic pathologies but pharmacological administration of full FXR agonists has been plagued by mechanism-based side effects. We have developed a modulator that partially activates FXR in vitro and in mice. Here we report the elucidation of the molecular mechanism that drives partial FXR activation by crystallography- and NMR-based structural biology. Natural and synthetic FXR agonists stabilize formation of an extended helix α11 and the α11-α12 loop upon binding. This strengthens a network of hydrogen bonds, repositions helix α12 and enables co-activator recruitment. Partial agonism in contrast is conferred by a kink in helix α11 that destabilizes the α11-α12 loop, a critical determinant for helix α12 orientation. Thereby, the synthetic partial agonist induces conformational states, capable of recruiting both co-repressors and co-activators leading to an equilibrium of co-activator and co-repressor binding.
format Online
Article
Text
id pubmed-6606567
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-66065672019-07-05 Molecular tuning of farnesoid X receptor partial agonism Merk, Daniel Sreeramulu, Sridhar Kudlinzki, Denis Saxena, Krishna Linhard, Verena Gande, Santosh L. Hiller, Fabian Lamers, Christina Nilsson, Ewa Aagaard, Anna Wissler, Lisa Dekker, Niek Bamberg, Krister Schubert-Zsilavecz, Manfred Schwalbe, Harald Nat Commun Article The bile acid-sensing transcription factor farnesoid X receptor (FXR) regulates multiple metabolic processes. Modulation of FXR is desired to overcome several metabolic pathologies but pharmacological administration of full FXR agonists has been plagued by mechanism-based side effects. We have developed a modulator that partially activates FXR in vitro and in mice. Here we report the elucidation of the molecular mechanism that drives partial FXR activation by crystallography- and NMR-based structural biology. Natural and synthetic FXR agonists stabilize formation of an extended helix α11 and the α11-α12 loop upon binding. This strengthens a network of hydrogen bonds, repositions helix α12 and enables co-activator recruitment. Partial agonism in contrast is conferred by a kink in helix α11 that destabilizes the α11-α12 loop, a critical determinant for helix α12 orientation. Thereby, the synthetic partial agonist induces conformational states, capable of recruiting both co-repressors and co-activators leading to an equilibrium of co-activator and co-repressor binding. Nature Publishing Group UK 2019-07-02 /pmc/articles/PMC6606567/ /pubmed/31266946 http://dx.doi.org/10.1038/s41467-019-10853-2 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Merk, Daniel
Sreeramulu, Sridhar
Kudlinzki, Denis
Saxena, Krishna
Linhard, Verena
Gande, Santosh L.
Hiller, Fabian
Lamers, Christina
Nilsson, Ewa
Aagaard, Anna
Wissler, Lisa
Dekker, Niek
Bamberg, Krister
Schubert-Zsilavecz, Manfred
Schwalbe, Harald
Molecular tuning of farnesoid X receptor partial agonism
title Molecular tuning of farnesoid X receptor partial agonism
title_full Molecular tuning of farnesoid X receptor partial agonism
title_fullStr Molecular tuning of farnesoid X receptor partial agonism
title_full_unstemmed Molecular tuning of farnesoid X receptor partial agonism
title_short Molecular tuning of farnesoid X receptor partial agonism
title_sort molecular tuning of farnesoid x receptor partial agonism
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6606567/
https://www.ncbi.nlm.nih.gov/pubmed/31266946
http://dx.doi.org/10.1038/s41467-019-10853-2
work_keys_str_mv AT merkdaniel moleculartuningoffarnesoidxreceptorpartialagonism
AT sreeramulusridhar moleculartuningoffarnesoidxreceptorpartialagonism
AT kudlinzkidenis moleculartuningoffarnesoidxreceptorpartialagonism
AT saxenakrishna moleculartuningoffarnesoidxreceptorpartialagonism
AT linhardverena moleculartuningoffarnesoidxreceptorpartialagonism
AT gandesantoshl moleculartuningoffarnesoidxreceptorpartialagonism
AT hillerfabian moleculartuningoffarnesoidxreceptorpartialagonism
AT lamerschristina moleculartuningoffarnesoidxreceptorpartialagonism
AT nilssonewa moleculartuningoffarnesoidxreceptorpartialagonism
AT aagaardanna moleculartuningoffarnesoidxreceptorpartialagonism
AT wisslerlisa moleculartuningoffarnesoidxreceptorpartialagonism
AT dekkerniek moleculartuningoffarnesoidxreceptorpartialagonism
AT bambergkrister moleculartuningoffarnesoidxreceptorpartialagonism
AT schubertzsilaveczmanfred moleculartuningoffarnesoidxreceptorpartialagonism
AT schwalbeharald moleculartuningoffarnesoidxreceptorpartialagonism